down arrow

Salarius Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: US79400X3052
USD
0.87
0.02 (1.77%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.830.91

52 Week

0.71108.00
Valuation
Technical
Day's Volume

CASH

26.51 k

Shareholding (Mar 2025)

FII

0.01%

Held by 3 FIIs

DII

98.88%

Held by 1 DIIs

Promoter

0.00%

How big is Salarius Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Salarius Pharmaceuticals, Inc. has a market capitalization of 2.23 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -5.56 million over the latest four quarters. As of Dec'24, shareholder's funds were 1.51 million and total assets were 3.02 million.

Market Cap: As of Jun 18, Salarius Pharmaceuticals, Inc. has a market capitalization of 2.23 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Salarius Pharmaceuticals reported net sales of 0.00 million and a net profit of -5.56 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 1.51 million, while total assets were reported at 3.02 million.

Read More

What does Salarius Pharmaceuticals, Inc. do?

22-Jun-2025

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing targeted therapies for pediatric and other cancers. It has a market capitalization of $2.23 million and reported a net profit loss of $2 million as of March 2025.

Overview: <BR>Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company developing targeted therapies for pediatric and other cancers, including solid tumors, and operates within the Miscellaneous industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2.23 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.69 <BR>Return on Equity: -557.00% <BR>Price to Book: 2.23 <BR><BR>Contact Details: <BR>Address: 2450 Holcombe Blvd Ste J-608, HOUSTON TX: 77021-2041 <BR>Tel: 1 617 8741821 <BR>Fax: 1 302 6555049 <BR>Website: http://www.flex-pharma.com/

Read More

Who are in the management team of Salarius Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Salarius Pharmaceuticals, Inc. includes Dr. William McVicar (Chairman), Mr. David Arthur (CEO), Dr. Bruce McCreedy (Interim Chief Scientific Officer), Dr. Paul Lammers (Lead Independent Director), and several independent directors: Ms. Tess Burleson, Mr. Arnold Hanish, and Mr. Jonathan Lieber. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Salarius Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. William McVicar, Chairman of the Board<BR>- Mr. David Arthur, President, Chief Executive Officer, and Director<BR>- Dr. Bruce McCreedy, Interim Chief Scientific Officer and Director<BR>- Dr. Paul Lammers, Lead Independent Director<BR>- Ms. Tess Burleson, Independent Director<BR>- Mr. Arnold Hanish, Independent Director<BR>- Mr. Jonathan Lieber, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Salarius Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of August 5, 2022, Salarius Pharmaceuticals, Inc. is considered overvalued with a significant downgrade in investment appeal due to its negative Return on Equity and poor stock performance, contrasting sharply with struggling peers.

As of 5 August 2022, the valuation grade for Salarius Pharmaceuticals, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is assessed as overvalued given its current financial metrics, particularly with a Price to Book Value of 1.54 and an EV to EBIT of just 0.03. Notably, the Return on Capital Employed (ROCE) is extraordinarily high at 349.78%, but this is overshadowed by a staggering Return on Equity (ROE) of -557.00%, reflecting severe losses.<BR><BR>In comparison to its peers, Salarius Pharmaceuticals shows a stark contrast with companies like OpGen, Inc. and BTC Digital Ltd., which have P/E ratios of -2.4932 and -9.9632, respectively, indicating that they are also struggling. The lack of profitability is evident across the board, as reflected in the negative EV to EBITDA ratios for its peers. The company's stock has performed poorly over the past year, down 58.33%, while the S&P 500 has gained 10.26%, further reinforcing the notion that Salarius is overvalued in its current state.

Read More

Is Salarius Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Salarius Pharmaceuticals shows a shift from mildly bearish to mildly bullish, with mixed indicators: bearish weekly MACD and RSI, mildly bullish monthly MACD, bearish daily moving averages, and bullish On-Balance Volume, while significantly underperforming the S&P 500 with a year-to-date return of -83.48%.

As of 25 August 2025, the technical trend for Salarius Pharmaceuticals, Inc. has changed from mildly bearish to mildly bullish. However, the overall stance remains mixed. The weekly MACD and RSI are bearish, while the monthly MACD is mildly bullish, indicating some potential for upward movement. The moving averages are bearish on a daily basis, and the Dow Theory shows no trend weekly but is bearish monthly. Despite this, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames, suggesting accumulation.<BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -83.48% compared to the S&P 500's 12.22%. This stark contrast highlights the challenges facing the stock despite the recent trend change.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.79

stock-summary
Return on Equity

510.34%

stock-summary
Price to Book

-2.37

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-81.86%
0%
-81.86%
6 Months
-92.74%
0%
-92.74%
1 Year
-95.88%
0%
-95.88%
2 Years
-98.95%
0%
-98.95%
3 Years
-52.69%
0%
-52.69%
4 Years
-99.95%
0%
-99.95%
5 Years
-99.97%
0%
-99.97%

Salarius Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Salarius Pharmaceuticals, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for Salarius Pharmaceuticals, Inc. has changed from mildly bearish to mildly bullish. However, the overall stance remains mixed. The weekly MACD and RSI are bearish, while the monthly MACD is mildly bullish, indicating some potential for upward movement. The moving averages are bearish on a daily basis, and the Dow Theory shows no trend weekly but is bearish monthly. Despite this, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames, suggesting accumulation. In terms of performance, the stock has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -83.48% compared to the S&P 500's 12.22%. This stark contrast highlights the challenges facing the stock despite the recent trend change....

Read More
Salarius Pharmaceuticals Stock Plummets to 52-Week Low of $4.23

Salarius Pharmaceuticals Stock Plummets to 52-Week Low of $4.23

Salarius Pharmaceuticals, Inc. has reached a new 52-week low, contrasting with its previous high. Despite a year-over-year performance increase, the company faces volatility and challenges in the industry. With a market cap of USD 2 million, it operates at a loss and has notable financial metrics that raise concerns.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
7.61%
EBIT to Interest (avg)
-11.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.69
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.64%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.54
EV to EBIT
0.03
EV to EBITDA
0.03
EV to Capital Employed
0.09
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
349.78%
ROE (Latest)
-557.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (1.1%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 41.18% vs -13.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-1.70",
          "chgp": "41.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-1.70",
          "chgp": "41.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 55.20% vs 60.44% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-12.90",
          "chgp": "55.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.60",
          "val2": "-12.50",
          "chgp": "55.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.00
-1.70
41.18%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.00
-1.70
41.18%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 41.18% vs -13.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.70
-12.90
55.81%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.60
-12.50
55.20%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 55.20% vs 60.44% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Salarius Pharmaceuticals, Inc. stock-summary
stock-summary
Salarius Pharmaceuticals, Inc.
Miscellaneous
Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
Company Coordinates stock-summary
Company Details
2450 Holcombe Blvd Ste J-608 , HOUSTON TX : 77021-2041
stock-summary
Tel: 1 617 8741821
stock-summary
http://www.flex-pharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."